

Arkansas PASSE

Pharmacy Policy Updates

March 2024

The following policies are effective April 1, 2024



AT CARESOURCE, WE LISTEN TO OUR PROVIDERS, AND WE STREAMLINE OUR BUSINESS PRACTICES TO MAKE IT EASIER FOR YOU TO WORK WITH US.

We have worked to create a predictable cycle for releasing administrative, pharmacy and reimbursement policies, so you know what to expect.

Check back each month for a consolidated network notification of policy updates from CareSource.

HOW TO USE THIS NETWORK NOTIFICATION

- Reference the list of policy updates.
- Note the effective date and impacted plans for each policy.
- Click the hyperlinked policy title to open the webpage containing the policy location.

FIND OUR POLICIES ONLINE

To access all CareSource policies, visit [CareSource.com](https://www.caresource.com) > Providers > Tools & Resources > [Provider Policies](#). Select your plan and state, then Pharmacy, Reimbursement or Administrative. Each policy page has an archive where you can find previous versions of policies.

PHARMACY POLICY UPDATES

POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
IZERVAY (AVACINCAPTAD PEGOL)	4/1/2024	ARKANSAS PASSE	NEW POLICY
EYLEA AND EYLEA HD (AFLIBERCEPT)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
VISUDYNE (VERTEPORFIN)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
XIPIRE (TRIAMCINOLONE)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
RETISERT (FLUOCINOLONE ACETONIDE)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
YUTIQ (FLUOCINOLONE ACETONIDE)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
ILUVIEN (FLUOCINOLONE ACETONIDE)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
OZURDEX (DEXAMETHASONE)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
VABYSMO (FARICIMAB-SVOA)	4/1/2024	ARKANSAS PASSE	REVISED POLICY

PHARMACY POLICY UPDATES

POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
MACRILEN (MACIMORELIN)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
OXLUMO (LUMASIRAN)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
DAXXIFY (DAXIBOTULINUMTOXINA- LANM)	4/1/2024	ARKANSAS PASSE	NEW POLICY
MYOBLOC (RIMABOTULINUMTOXINB)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
DYSPORT (ABOBOTULINUMTOXINA)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
XEOMIN (INCOBOTULINUMTOXINA)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
BOTOX (ONABOTULINUMTOXINA)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
POMBILTI (CIPAGLUCOSIDASE ALFA-ATGA) AND OPFOLDA (MIGLUSTAT)	4/1/2024	ARKANSAS PASSE	NEW POLICY

PHARMACY POLICY UPDATES

POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
LUMIZYME (ALGLUCOSIDASE ALFA)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
NEXVIAZYME (AVALGLUCOSIDASE ALFA-NGP)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
CINQAIR (RESLIZUMAB)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
GAMIFANT (EMAPALUMAB-LZSG)	4/1/2024	ARKANSAS PASSE	REVISED POLICY
VEOPOZ (POZELIMAB)	4/1/2024	ARKANSAS PASSE	NEW POLICY
RITUXIMAB	4/1/2024	ARKANSAS PASSE	REVISED POLICY